Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.33 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622611 | 0.92 | JAK2 (0.44) | JAK2JAK1TYK2JAK3ITGB3 | |
| SCHEMBL13634045 | 0.89 | JAK2 (0.37) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13633094 | 0.87 | JAK2 (0.39) | JAK2JAK1TYK2JAK3ITGB3 | |
| SCHEMBL13633016 | 0.85 | ALDH1A1 (0.34) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13632989 | 0.84 | ALK (0.39) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL1073959 | 0.84 | ALK (0.51) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL1073047 | 0.83 | JAK2 (0.45) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13633246 | 0.83 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13634064 | 0.82 | MAPK1 (0.38) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13632935 | 0.81 | ALK (0.36) | JAK2JAK1TYK2JAK3ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | JAK2 1/4885JAK1 2/4885TYK2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.